Stage IVs/locally advanced bc
T-DM1 treatment resulted in noninferior, but not superior, progression-free survival (PFS) compared with trastuzumab plus a taxane (HT) in patients with locally advanced or metastatic HER2-positive breast cancer.
from ASCO 2015:
https://am.asco.org/phase-iii-marianne-trial-results